Industry Insights
Sep 14, 2026 · 1 min read · 28,878 views
Cellares and Ori Biotech's new cell therapy manufacturing contracts
A
Ava Sinclair
Editorial · Sep 14, 2026
CART01; Ori bags $120M deal; Reckitt invests $600M in US; Astellas expands Ireland; Hovione opens NJ facility
← Previous
The most exciting biotech startups of 2026: How we selected this year's list
Next →
Insurers play catch-up
